Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Test af kontinuerlig versus intermitterende behandling med undersøgelseslægemidlet Zanubrutinib til ældre patienter med tidligere ubehandlet kappecellelymfom

2. november 2026 opdateret af: Alliance for Clinical Trials in Oncology

Et randomiseret fase 3-forsøg med kontinuerlig vs. intermitterende vedligeholdelsesterapi med Zanubrutinib som forhåndsbehandling hos ældre patienter med mantelcellelymfom

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

PRIMARY OBJECTIVE:

I. To compare time to first progression or death (progression free survival [PFS]1) with continuous treatment (Arm A) and time to second progression or death (PFS2) with intermittent treatment that is restarted at first progression (Arm B).

KEY SECONDARY OBJECTIVE:

I. To compare overall survival between patients who achieve a complete remission (CR) with induction therapy subsequently treated with continuous treatment versus (vs.) intermittent treatment as part of maintenance therapy.

SECONDARY OBJECTIVES:

I. To determine overall response rate (ORR) and CR rate to induction therapy with zanubrutinib and rituximab in previously untreated MCL.

II. To determine adverse events during induction and post-induction in each study arm (Arm A and B) by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

III. To determine PFS1, event free survival (EFS) and overall survival (OS) in each study arm (A and B).

IV. To determine the overall response rate (ORR) and complete response rate (CR) after restarting zanubrutinib, following the first progression, in the intermittent treatment arm (Arm B).

V. To compare burden of symptomatic adverse events (AEs) as assessed by Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) between patients randomized to Arm A versus Arm B.

QUALITY OF LIFE PRIMARY OBJECTIVE:

I. To compare health-related quality of life (QOL) at 12 months post-randomization as assessed by the Functional Assessment of Cancer Therapy (FACT) Lymphoma Symptom Index-18 (FLYMSI-18) total score between patients randomized to Arm A versus Arm B.

QUALITY OF LIFE SECONDARY OBJECTIVES:

I. To compare health-related QOL at other time points as assessed by the FLYMSI-18 total score between patients randomized to Arm A versus Arm B.

II. To compare burden of symptomatic AEs as assessed by PRO-CTCAE between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment.

QUALITY OF LIFE EXPLORATORY OBJECTIVES:

I. To compare the geriatric functional and cognitive PRO as assessed by Elderly Functional Index (ELFI) and Neurology (Neuro) QOL in Arm A versus Arm B.

II. To compare cognitive function at various time points as assessed by the Neuro-QOL between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment.

EXPLORATORY OBJECTIVES:

I. To evaluate the completion rate of a lymphoma-specific patient assessment of life survey (PALS) with patient directed questions on life, health, and social determinants of health (SDH) and assess the impact of the survey collected data on outcomes for all enrolled patients (study arms A and B).

II. To evaluate minimal residual disease (MRD) in those patients who achieve a CR after induction therapy (arms A and B) and how detectable MRD status changes after continued therapy vs. discontinuation of therapy (i.e. arms A vs. B).

OUTLINE:

INDUCTION THERAPY: Patients receive zanubrutinib orally (PO) twice daily (BID) on days 1-28 of each cycle and rituximab intravenously (IV) on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. . Patients undergo bone marrow biopsy and fluciclovine F18 (FDG) positron emission tomography (PET)/ computed tomography (CT) or CT throughout the trial. Patients may also undergo esophagogastroduodenoscopy (EGD) and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.

MAINTENANCE THERAPY: Patients achieving a CR after induction therapy are randomized to 1 of 2 arms.

ARM A: Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days until first disease progression on study. Patients undergo CT or magnetic resonance imaging (MRI) or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.

ARM B: Patients undergo observation until first disease progression and then receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial and may undergo bone marrow biopsy on study.

After completion of study treatment, patients are followed within 30 days and every 6 months for 10 years.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

421

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72205
        • Rekruttering
        • University of Arkansas for Medical Sciences
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 501-686-8274
        • Ledende efterforsker:
          • Cesar Gentille
    • California
      • Beverly Hills, California, Forenede Stater, 90211
      • Duarte, California, Forenede Stater, 91010
        • Aktiv, ikke rekrutterende
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, Forenede Stater, 92618
        • Aktiv, ikke rekrutterende
        • City of Hope at Irvine Lennar
      • Los Angeles, California, Forenede Stater, 90048
        • Rekruttering
        • Cedars-Sinai Medical Center
        • Ledende efterforsker:
          • Justin M. Darrah
        • Kontakt:
    • Connecticut
      • Derby, Connecticut, Forenede Stater, 06418
        • Rekruttering
        • Smilow Cancer Hospital-Derby Care Center
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Fairfield, Connecticut, Forenede Stater, 06824
        • Rekruttering
        • Smilow Cancer Hospital Care Center-Fairfield
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Glastonbury, Connecticut, Forenede Stater, 06033
        • Rekruttering
        • Smilow Cancer Hospital Care Center at Glastonbury
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Greenwich, Connecticut, Forenede Stater, 06830
        • Rekruttering
        • Smilow Cancer Hospital Care Center at Greenwich
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Guilford, Connecticut, Forenede Stater, 06437
        • Rekruttering
        • Smilow Cancer Hospital Care Center - Guilford
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Hartford, Connecticut, Forenede Stater, 06105
        • Rekruttering
        • Smilow Cancer Hospital Care Center at Saint Francis
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • New Haven, Connecticut, Forenede Stater, 06520
        • Rekruttering
        • Yale University
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • North Haven, Connecticut, Forenede Stater, 06473
        • Rekruttering
        • Yale-New Haven Hospital North Haven Medical Center
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Stamford, Connecticut, Forenede Stater, 06902
        • Rekruttering
        • Smilow Cancer Hospital Care Center at Long Ridge
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Torrington, Connecticut, Forenede Stater, 06790
        • Rekruttering
        • Smilow Cancer Hospital-Torrington Care Center
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Trumbull, Connecticut, Forenede Stater, 06611
        • Rekruttering
        • Smilow Cancer Hospital Care Center-Trumbull
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Waterbury, Connecticut, Forenede Stater, 06708
        • Rekruttering
        • Smilow Cancer Hospital-Waterbury Care Center
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
      • Waterford, Connecticut, Forenede Stater, 06385
        • Rekruttering
        • Smilow Cancer Hospital Care Center - Waterford
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
    • Delaware
      • Newark, Delaware, Forenede Stater, 19713
        • Rekruttering
        • Helen F Graham Cancer Center
        • Ledende efterforsker:
          • Gregory A. Masters
        • Kontakt:
      • Newark, Delaware, Forenede Stater, 19713
        • Rekruttering
        • Medical Oncology Hematology Consultants PA
        • Ledende efterforsker:
          • Gregory A. Masters
        • Kontakt:
    • Georgia
      • Albany, Georgia, Forenede Stater, 31701
        • Rekruttering
        • Phoebe Putney Memorial Hospital
        • Ledende efterforsker:
          • Locke J. Bryan
        • Kontakt:
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Hospital/Winship Cancer Institute
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 404-778-1868
        • Ledende efterforsker:
          • Jonathon B. Cohen
      • Atlanta, Georgia, Forenede Stater, 30303
        • Rekruttering
        • Grady Health System
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 404-778-1868
        • Ledende efterforsker:
          • Jonathon B. Cohen
      • Atlanta, Georgia, Forenede Stater, 30308
        • Rekruttering
        • Emory University Hospital Midtown
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-946-7447
        • Ledende efterforsker:
          • Jonathon B. Cohen
      • Atlanta, Georgia, Forenede Stater, 30342
        • Rekruttering
        • Emory Saint Joseph's Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 404-851-7115
        • Ledende efterforsker:
          • Jonathon B. Cohen
      • Augusta, Georgia, Forenede Stater, 30912
        • Rekruttering
        • Augusta University Medical Center
        • Ledende efterforsker:
          • Locke J. Bryan
        • Kontakt:
      • Johns Creek, Georgia, Forenede Stater, 30097
        • Rekruttering
        • Emory Johns Creek Hospital
        • Ledende efterforsker:
          • Jonathon B. Cohen
        • Kontakt:
    • Idaho
      • Boise, Idaho, Forenede Stater, 83712
        • Rekruttering
        • Saint Luke's Cancer Institute - Boise
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Boise, Idaho, Forenede Stater, 83706
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Boise
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Caldwell, Idaho, Forenede Stater, 83605
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Caldwell
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Coeur d'Alene, Idaho, Forenede Stater, 83814
        • Rekruttering
        • Kootenai Health - Coeur d'Alene
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
      • Fruitland, Idaho, Forenede Stater, 83619
        • Rekruttering
        • Saint Luke's Cancer Institute - Fruitland
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Meridian, Idaho, Forenede Stater, 83642
        • Rekruttering
        • Saint Luke's Cancer Institute - Meridian
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Nampa, Idaho, Forenede Stater, 83687
        • Rekruttering
        • Saint Luke's Cancer Institute - Nampa
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Nampa, Idaho, Forenede Stater, 83687
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Nampa
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Post Falls, Idaho, Forenede Stater, 83854
        • Rekruttering
        • Kootenai Clinic Cancer Services - Post Falls
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
      • Sandpoint, Idaho, Forenede Stater, 83864
        • Rekruttering
        • Kootenai Clinic Cancer Services - Sandpoint
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
    • Illinois
      • Bloomington, Illinois, Forenede Stater, 61704
        • Rekruttering
        • Illinois CancerCare-Bloomington
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Canton, Illinois, Forenede Stater, 61520
        • Rekruttering
        • Illinois CancerCare-Canton
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Carthage, Illinois, Forenede Stater, 62321
        • Rekruttering
        • Illinois CancerCare-Carthage
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Chicago, Illinois, Forenede Stater, 60612
        • Rekruttering
        • University of Illinois
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 312-355-3046
        • Ledende efterforsker:
          • Carlos Galvez
      • Chicago, Illinois, Forenede Stater, 60606
        • Rekruttering
        • Alliance for Clinical Trials in Oncology
        • Ledende efterforsker:
          • Anne W. Beaven
        • Kontakt:
      • Danville, Illinois, Forenede Stater, 61832
        • Rekruttering
        • Carle at The Riverfront
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
        • Kontakt:
      • Decatur, Illinois, Forenede Stater, 62526
        • Rekruttering
        • Cancer Care Specialists of Illinois - Decatur
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
      • Decatur, Illinois, Forenede Stater, 62526
        • Rekruttering
        • Decatur Memorial Hospital
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
      • Dixon, Illinois, Forenede Stater, 61021
        • Rekruttering
        • Illinois CancerCare-Dixon
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 815-285-7800
      • Effingham, Illinois, Forenede Stater, 62401
        • Rekruttering
        • Carle Physician Group-Effingham
        • Kontakt:
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
      • Effingham, Illinois, Forenede Stater, 62401
        • Rekruttering
        • Crossroads Cancer Center
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
      • Eureka, Illinois, Forenede Stater, 61530
        • Rekruttering
        • Illinois CancerCare-Eureka
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Evanston, Illinois, Forenede Stater, 60201
        • Rekruttering
        • NorthShore University HealthSystem-Evanston Hospital
        • Ledende efterforsker:
          • Amy Y. Wang
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
      • Galesburg, Illinois, Forenede Stater, 61401
        • Rekruttering
        • Illinois CancerCare-Galesburg
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Glenview, Illinois, Forenede Stater, 60026
        • Rekruttering
        • NorthShore University HealthSystem-Glenbrook Hospital
        • Ledende efterforsker:
          • Amy Y. Wang
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
      • Highland Park, Illinois, Forenede Stater, 60035
        • Rekruttering
        • NorthShore University HealthSystem-Highland Park Hospital
        • Ledende efterforsker:
          • Amy Y. Wang
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
      • Kewanee, Illinois, Forenede Stater, 61443
        • Rekruttering
        • Illinois CancerCare-Kewanee Clinic
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Macomb, Illinois, Forenede Stater, 61455
        • Rekruttering
        • Illinois CancerCare-Macomb
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Mattoon, Illinois, Forenede Stater, 61938
        • Rekruttering
        • Carle Physician Group-Mattoon/Charleston
        • Kontakt:
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
      • Mount Vernon, Illinois, Forenede Stater, 62864
        • Rekruttering
        • SSM Health Good Samaritan
        • Ledende efterforsker:
          • Jay W. Carlson
        • Kontakt:
      • O'Fallon, Illinois, Forenede Stater, 62269
        • Rekruttering
        • Cancer Care Center of O'Fallon
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
      • Ottawa, Illinois, Forenede Stater, 61350
        • Rekruttering
        • Illinois CancerCare-Ottawa Clinic
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Pekin, Illinois, Forenede Stater, 61554
        • Rekruttering
        • Illinois CancerCare-Pekin
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Peoria, Illinois, Forenede Stater, 61615
        • Rekruttering
        • Illinois CancerCare-Peoria
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Peru, Illinois, Forenede Stater, 61354
        • Rekruttering
        • Illinois CancerCare-Peru
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Princeton, Illinois, Forenede Stater, 61356
        • Rekruttering
        • Illinois CancerCare-Princeton
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
      • Shiloh, Illinois, Forenede Stater, 62269
        • Rekruttering
        • Memorial Hospital East
        • Kontakt:
        • Ledende efterforsker:
          • Brad S. Kahl
      • Springfield, Illinois, Forenede Stater, 62702
        • Rekruttering
        • Southern Illinois University School of Medicine
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 217-545-7929
      • Springfield, Illinois, Forenede Stater, 62702
        • Rekruttering
        • Springfield Clinic
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-444-7541
      • Springfield, Illinois, Forenede Stater, 62781
        • Rekruttering
        • Springfield Memorial Hospital
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
      • Urbana, Illinois, Forenede Stater, 61801
        • Rekruttering
        • Carle Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
      • Washington, Illinois, Forenede Stater, 61571
        • Rekruttering
        • Illinois CancerCare - Washington
        • Kontakt:
        • Ledende efterforsker:
          • Bryan A. Faller
    • Indiana
      • Crown Point, Indiana, Forenede Stater, 46307
        • Rekruttering
        • Northwest Cancer Center - Crown Point
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
        • Kontakt:
      • Dyer, Indiana, Forenede Stater, 46311
        • Rekruttering
        • Northwest Oncology LLC
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 219-924-8178
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
      • Hobart, Indiana, Forenede Stater, 46342
        • Rekruttering
        • Northwest Cancer Center - Hobart
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 219-947-1795
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
      • Hobart, Indiana, Forenede Stater, 46342
        • Rekruttering
        • Saint Mary Medical Center
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
        • Kontakt:
      • Indianapolis, Indiana, Forenede Stater, 46312
        • Rekruttering
        • Saint Catherine Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
      • Munster, Indiana, Forenede Stater, 46321
        • Rekruttering
        • The Community Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 219-836-3349
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
      • Munster, Indiana, Forenede Stater, 46321
        • Rekruttering
        • Women's Diagnostic Center - Munster
        • Kontakt:
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
      • Valparaiso, Indiana, Forenede Stater, 46383
        • Rekruttering
        • Northwest Cancer Center - Valparaiso
        • Ledende efterforsker:
          • Maria T. Grosse-Perdekamp
        • Kontakt:
    • Iowa
      • Ames, Iowa, Forenede Stater, 50010
        • Rekruttering
        • Mary Greeley Medical Center
        • Ledende efterforsker:
          • Joseph J. Merchant
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-956-4132
      • Ames, Iowa, Forenede Stater, 50010
        • Rekruttering
        • McFarland Clinic - Ames
        • Ledende efterforsker:
          • Joseph J. Merchant
        • Kontakt:
      • Ankeny, Iowa, Forenede Stater, 50023
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Boone, Iowa, Forenede Stater, 50036
        • Suspenderet
        • McFarland Clinic - Boone
      • Carroll, Iowa, Forenede Stater, 51401
        • Rekruttering
        • Saint Anthony Regional Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Clive, Iowa, Forenede Stater, 50325
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forenede Stater, 50314
        • Rekruttering
        • Broadlawns Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-282-2200
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forenede Stater, 50314
        • Rekruttering
        • Mercy Medical Center - Des Moines
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Richard L. Deming
      • Des Moines, Iowa, Forenede Stater, 50309
        • Rekruttering
        • Iowa Methodist Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-6727
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forenede Stater, 50309
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forenede Stater, 50314
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
      • Fort Dodge, Iowa, Forenede Stater, 50501
        • Rekruttering
        • McFarland Clinic - Trinity Cancer Center
        • Ledende efterforsker:
          • Joseph J. Merchant
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-956-4132
      • Fort Dodge, Iowa, Forenede Stater, 50501
        • Rekruttering
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
        • Ledende efterforsker:
          • Seema Harichand-Herdt
        • Kontakt:
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • University of Iowa/Holden Comprehensive Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-237-1225
        • Ledende efterforsker:
          • Eric Mou
      • Jefferson, Iowa, Forenede Stater, 50129
        • Suspenderet
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Forenede Stater, 50158
        • Rekruttering
        • McFarland Clinic - Marshalltown
        • Ledende efterforsker:
          • Joseph J. Merchant
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-956-4132
      • Waukee, Iowa, Forenede Stater, 50263
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Ledende efterforsker:
          • Seema Harichand-Herdt
    • Kansas
      • Hays, Kansas, Forenede Stater, 67601
        • Rekruttering
        • HaysMed
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 785-623-5774
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • University of Kansas Cancer Center
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
      • Lawrence, Kansas, Forenede Stater, 66044
        • Rekruttering
        • Lawrence Memorial Hospital
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
      • Leavenworth, Kansas, Forenede Stater, 66048
        • Suspenderet
        • Veteran Administration Eastern Kansas Healthcare
      • Olathe, Kansas, Forenede Stater, 66061
        • Rekruttering
        • The University of Kansas Cancer Center - Olathe
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
      • Overland Park, Kansas, Forenede Stater, 66210
        • Rekruttering
        • University of Kansas Cancer Center-Overland Park
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
      • Pittsburg, Kansas, Forenede Stater, 66762
        • Rekruttering
        • Freeman Physician Group of Pittsburg
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
      • Salina, Kansas, Forenede Stater, 67401
        • Rekruttering
        • Salina Regional Health Center
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
      • Topeka, Kansas, Forenede Stater, 66606
        • Rekruttering
        • University of Kansas Health System Saint Francis Campus
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 785-295-8000
      • Westwood, Kansas, Forenede Stater, 66205
        • Rekruttering
        • University of Kansas Hospital-Westwood Cancer Center
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40202
        • Rekruttering
        • The James Graham Brown Cancer Center at University of Louisville
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 502-562-3429
        • Ledende efterforsker:
          • Hassaan Yasin
      • Louisville, Kentucky, Forenede Stater, 40245
        • Rekruttering
        • UofL Health Medical Center Northeast
        • Kontakt:
        • Ledende efterforsker:
          • Hassaan Yasin
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48106
        • Rekruttering
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Bay City, Michigan, Forenede Stater, 48706
        • Rekruttering
        • McLaren Cancer Institute-Bay City
        • Ledende efterforsker:
          • Dipenkumar Modi
        • Kontakt:
      • Brighton, Michigan, Forenede Stater, 48114
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Brighton, Michigan, Forenede Stater, 48114
        • Rekruttering
        • Trinity Health Medical Center - Brighton
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Canton, Michigan, Forenede Stater, 48188
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Canton, Michigan, Forenede Stater, 48188
        • Rekruttering
        • Trinity Health Medical Center - Canton
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Chelsea, Michigan, Forenede Stater, 48118
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Chelsea, Michigan, Forenede Stater, 48118
      • Clarkston, Michigan, Forenede Stater, 48346
        • Rekruttering
        • McLaren Cancer Institute-Clarkston
        • Ledende efterforsker:
          • Dipenkumar Modi
        • Kontakt:
      • Detroit, Michigan, Forenede Stater, 48201
        • Rekruttering
        • Wayne State University/Karmanos Cancer Institute
        • Ledende efterforsker:
          • Dipenkumar Modi
        • Kontakt:
      • Farmington Hills, Michigan, Forenede Stater, 48334
        • Rekruttering
        • Weisberg Cancer Treatment Center
        • Ledende efterforsker:
          • Dipenkumar Modi
        • Kontakt:
      • Farmington Hills, Michigan, Forenede Stater, 48336
        • Rekruttering
        • Corewell Health Farmington Hills Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 248-551-7695
        • Ledende efterforsker:
          • Andrew A. Muskovitz
      • Flint, Michigan, Forenede Stater, 48503
        • Rekruttering
        • Genesys Hurley Cancer Institute
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Flint, Michigan, Forenede Stater, 48503
        • Rekruttering
        • Hurley Medical Center
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Flint, Michigan, Forenede Stater, 48532
        • Rekruttering
        • McLaren Cancer Institute-Flint
        • Ledende efterforsker:
          • Dipenkumar Modi
        • Kontakt:
      • Flint, Michigan, Forenede Stater, 48503
        • Suspenderet
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Forenede Stater, 48503
        • Rekruttering
        • Cancer Hematology Centers - Flint
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Lansing, Michigan, Forenede Stater, 48912
        • Rekruttering
        • University of Michigan Health - Sparrow Lansing
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Lapeer, Michigan, Forenede Stater, 48446
        • Rekruttering
        • McLaren Cancer Institute-Lapeer Region
        • Ledende efterforsker:
          • Dipenkumar Modi
        • Kontakt:
      • Livonia, Michigan, Forenede Stater, 48154
        • Rekruttering
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Macomb, Michigan, Forenede Stater, 48044
        • Rekruttering
        • Henry Ford Saint John Hospital - Macomb Medical
        • Ledende efterforsker:
          • Christopher M. Reynolds
        • Kontakt:
      • Mount Pleasant, Michigan, Forenede Stater, 48858
        • Rekruttering
        • McLaren Cancer Institute-Central Michigan
        • Ledende efterforsker:
          • Dipenkumar Modi
        • Kontakt:
      • Petoskey, Michigan, Forenede Stater, 49770
        • Rekruttering
        • McLaren Cancer Institute-Northern Michigan
        • Ledende efterforsker:
          • Dipenkumar Modi
        • Kontakt:
      • Pontiac, Michigan, Forenede Stater, 48341
        • Rekruttering
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Royal Oak, Michigan, Forenede Stater, 48073
        • Rekruttering
        • Corewell Health William Beaumont University Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 248-551-7695
        • Ledende efterforsker:
          • Andrew A. Muskovitz
      • Saginaw, Michigan, Forenede Stater, 48604
        • Suspenderet
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, Forenede Stater, 48601
        • Rekruttering
        • MyMichigan Medical Center Saginaw
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Tawas City, Michigan, Forenede Stater, 48764
        • Rekruttering
        • MyMichigan Medical Center Tawas
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Troy, Michigan, Forenede Stater, 48085
        • Rekruttering
        • Corewell Health Beaumont Troy Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 248-551-7695
        • Ledende efterforsker:
          • Andrew A. Muskovitz
      • West Branch, Michigan, Forenede Stater, 48661
        • Suspenderet
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Ypsilanti, Michigan, Forenede Stater, 48106
      • Ypsilanti, Michigan, Forenede Stater, 48197
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
    • Minnesota
      • Bemidji, Minnesota, Forenede Stater, 56601
      • Brainerd, Minnesota, Forenede Stater, 56401
        • Rekruttering
        • Essentia Health Saint Joseph's Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Bret E. Friday
      • Coon Rapids, Minnesota, Forenede Stater, 55433
        • Rekruttering
        • Mercy Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
      • Deer River, Minnesota, Forenede Stater, 56636
        • Rekruttering
        • Essentia Health - Deer River Clinic
        • Kontakt:
        • Ledende efterforsker:
          • Bret E. Friday
      • Duluth, Minnesota, Forenede Stater, 55805
        • Rekruttering
        • Essentia Health Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Bret E. Friday
      • Edina, Minnesota, Forenede Stater, 55435
        • Rekruttering
        • Minnesota Oncology - Edina
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
      • Hibbing, Minnesota, Forenede Stater, 55746
        • Rekruttering
        • Essentia Health Hibbing Clinic
        • Ledende efterforsker:
          • Bret E. Friday
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 218-786-3308
      • Maplewood, Minnesota, Forenede Stater, 55109
        • Rekruttering
        • Saint John's Hospital - Healtheast
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Rekruttering
        • Abbott-Northwestern Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
      • Minneapolis, Minnesota, Forenede Stater, 55415
        • Rekruttering
        • Hennepin County Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
      • Saint Cloud, Minnesota, Forenede Stater, 56303
        • Rekruttering
        • Coborn Cancer Center at Saint Cloud Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Donald J. Jurgens
      • Saint Louis Park, Minnesota, Forenede Stater, 55416
        • Rekruttering
        • Park Nicollet Clinic - Saint Louis Park
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
      • Saint Paul, Minnesota, Forenede Stater, 55101
        • Rekruttering
        • Regions Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
      • Saint Paul, Minnesota, Forenede Stater, 55102
        • Rekruttering
        • United Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
      • Sandstone, Minnesota, Forenede Stater, 55072
        • Rekruttering
        • Essentia Health Sandstone
        • Kontakt:
        • Ledende efterforsker:
          • Bret E. Friday
      • Virginia, Minnesota, Forenede Stater, 55792
        • Rekruttering
        • Essentia Health Virginia Clinic
        • Kontakt:
        • Ledende efterforsker:
          • Bret E. Friday
      • Woodbury, Minnesota, Forenede Stater, 55125
        • Rekruttering
        • Minnesota Oncology Hematology PA-Woodbury
        • Kontakt:
        • Ledende efterforsker:
          • Yan Ji
    • Missouri
      • Cape Girardeau, Missouri, Forenede Stater, 63703
        • Rekruttering
        • Saint Francis Medical Center
        • Ledende efterforsker:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 573-334-2230
          • E-mail: sfmc@sfmc.net
      • Chesterfield, Missouri, Forenede Stater, 63017
        • Rekruttering
        • Saint Luke's Hospital
        • Ledende efterforsker:
          • Mark J. Fesler
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-205-6936
      • City of Saint Peters, Missouri, Forenede Stater, 63376
        • Rekruttering
        • Siteman Cancer Center at Saint Peters Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Brad S. Kahl
      • Creve Coeur, Missouri, Forenede Stater, 63141
        • Rekruttering
        • Siteman Cancer Center at West County Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Brad S. Kahl
      • Kansas City, Missouri, Forenede Stater, 64154
        • Rekruttering
        • University of Kansas Cancer Center - North
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
      • Kansas City, Missouri, Forenede Stater, 64128
        • Rekruttering
        • Kansas City Veterans Affairs Medical Center
        • Ledende efterforsker:
          • Suman Kambhampati
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-525-1483
      • Kansas City, Missouri, Forenede Stater, 64108
        • Rekruttering
        • University Health Truman Medical Center
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 816-404-4375
      • Kansas City, Missouri, Forenede Stater, 64116
        • Rekruttering
        • University of Kansas Cancer Center - Briarcliff
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 913-588-3671
      • Lee's Summit, Missouri, Forenede Stater, 64064
        • Rekruttering
        • University of Kansas Cancer Center - Lee's Summit
        • Ledende efterforsker:
          • Marc S. Hoffmann
        • Kontakt:
      • North Kansas City, Missouri, Forenede Stater, 64116
        • Suspenderet
        • University of Kansas Cancer Center at North Kansas City Hospital
      • Springfield, Missouri, Forenede Stater, 65804
        • Rekruttering
        • Mercy Hospital Springfield
        • Ledende efterforsker:
          • Jay W. Carlson
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 417-269-4520
      • Springfield, Missouri, Forenede Stater, 65807
        • Rekruttering
        • CoxHealth South Hospital
        • Ledende efterforsker:
          • Jay W. Carlson
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 417-269-4520
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Brad S. Kahl
      • St Louis, Missouri, Forenede Stater, 63128
        • Rekruttering
        • Mercy Hospital South
        • Ledende efterforsker:
          • Jay W. Carlson
        • Kontakt:
      • St Louis, Missouri, Forenede Stater, 63129
        • Rekruttering
        • Siteman Cancer Center-South County
        • Kontakt:
        • Ledende efterforsker:
          • Brad S. Kahl
      • St Louis, Missouri, Forenede Stater, 63136
        • Rekruttering
        • Siteman Cancer Center at Christian Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Brad S. Kahl
    • Montana
      • Anaconda, Montana, Forenede Stater, 59711
        • Rekruttering
        • Community Hospital of Anaconda
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
      • Billings, Montana, Forenede Stater, 59101
        • Rekruttering
        • Billings Clinic Cancer Center
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
      • Bozeman, Montana, Forenede Stater, 59715
        • Rekruttering
        • Bozeman Health Deaconess Hospital
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
      • Great Falls, Montana, Forenede Stater, 59405
        • Rekruttering
        • Benefis Sletten Cancer Institute
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
      • Kalispell, Montana, Forenede Stater, 59901
        • Rekruttering
        • Logan Health Medical Center
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
      • Missoula, Montana, Forenede Stater, 59804
        • Rekruttering
        • Community Medical Center
        • Ledende efterforsker:
          • John M. Schallenkamp
        • Kontakt:
    • Nebraska
      • Bellevue, Nebraska, Forenede Stater, 68123
        • Rekruttering
        • Nebraska Medicine-Bellevue
        • Ledende efterforsker:
          • Julie M. Vose
        • Kontakt:
      • Kearney, Nebraska, Forenede Stater, 68845
        • Rekruttering
        • Fred and Pamela Buffett Cancer Center - Kearney
        • Ledende efterforsker:
          • Julie M. Vose
        • Kontakt:
      • Omaha, Nebraska, Forenede Stater, 68198
        • Rekruttering
        • University of Nebraska Medical Center
        • Ledende efterforsker:
          • Julie M. Vose
        • Kontakt:
      • Omaha, Nebraska, Forenede Stater, 68118
        • Rekruttering
        • Nebraska Medicine-Village Pointe
        • Ledende efterforsker:
          • Julie M. Vose
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 402-559-5600
    • New Hampshire
      • Lebanon, New Hampshire, Forenede Stater, 03756
        • Rekruttering
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Charles Gaulin
    • New York
      • Buffalo, New York, Forenede Stater, 14263
        • Rekruttering
        • Roswell Park Cancer Institute
        • Kontakt:
        • Ledende efterforsker:
          • Chelsea Peterson
      • Camillus, New York, Forenede Stater, 13031
        • Rekruttering
        • Hematology Oncology Associates of CNY at Camillus
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 315-472-7504
        • Ledende efterforsker:
          • Steven M. Duffy
      • East Syracuse, New York, Forenede Stater, 13057
        • Rekruttering
        • Hematology Oncology Associates of Central New York-East Syracuse
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 315-472-7504
        • Ledende efterforsker:
          • Steven M. Duffy
      • Mineola, New York, Forenede Stater, 11501
        • Rekruttering
        • NYU Langone Hospital - Long Island
        • Ledende efterforsker:
          • Peter Martin
        • Kontakt:
      • New York, New York, Forenede Stater, 10016
        • Rekruttering
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • Ledende efterforsker:
          • Peter Martin
        • Kontakt:
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • NYP/Weill Cornell Medical Center
        • Ledende efterforsker:
          • Jia Ruan
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-746-1848
      • Rochester, New York, Forenede Stater, 14642
        • Rekruttering
        • University of Rochester
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 585-275-5830
        • Ledende efterforsker:
          • Paul M. Barr
      • Webster, New York, Forenede Stater, 14580
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27599
        • Rekruttering
        • UNC Lineberger Comprehensive Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Anne W. Beaven
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-275-3853
        • Ledende efterforsker:
          • Matthew S. McKinney
    • North Dakota
      • Bismarck, North Dakota, Forenede Stater, 58501
      • Fargo, North Dakota, Forenede Stater, 58122
      • Fargo, North Dakota, Forenede Stater, 58103
        • Rekruttering
        • Essentia Health Cancer Center-South University Clinic
        • Kontakt:
        • Ledende efterforsker:
          • Bret E. Friday
      • Fargo, North Dakota, Forenede Stater, 58122
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • Ohio State University Comprehensive Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • David A. Bond
    • Oklahoma
      • Lawton, Oklahoma, Forenede Stater, 73505
        • Rekruttering
        • Cancer Centers of Southwest Oklahoma Research
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-231-4440
        • Ledende efterforsker:
          • Taha Al-Juhaishi
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • University of Oklahoma Health Sciences Center
        • Kontakt:
        • Ledende efterforsker:
          • Taha Al-Juhaishi
      • Tulsa, Oklahoma, Forenede Stater, 74146
        • Rekruttering
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 918-505-3200
        • Ledende efterforsker:
          • Mark B. Jennings
    • Oregon
      • Newberg, Oregon, Forenede Stater, 97132
        • Rekruttering
        • Providence Newberg Medical Center
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Ontario, Oregon, Forenede Stater, 97914
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Ontario
        • Kontakt:
        • Ledende efterforsker:
          • Christopher M. Reynolds
      • Oregon City, Oregon, Forenede Stater, 97045
        • Rekruttering
        • Providence Willamette Falls Medical Center
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Portland, Oregon, Forenede Stater, 97213
        • Rekruttering
        • Providence Portland Medical Center
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Portland, Oregon, Forenede Stater, 97225
        • Rekruttering
        • Providence Saint Vincent Medical Center
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02903
        • Rekruttering
        • Rhode Island Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 401-444-1488
        • Ledende efterforsker:
          • Adam J. Olszewski
      • Westerly, Rhode Island, Forenede Stater, 02891
        • Rekruttering
        • Smilow Cancer Hospital Care Center - Westerly
        • Ledende efterforsker:
          • Shalin Kothari
        • Kontakt:
    • South Carolina
      • Boiling Springs, South Carolina, Forenede Stater, 29316
        • Rekruttering
        • Prisma Health Cancer Institute - Spartanburg
        • Ledende efterforsker:
          • Suzanne R. Fanning
        • Kontakt:
      • Charleston, South Carolina, Forenede Stater, 29425
        • Rekruttering
        • Medical University of South Carolina
        • Kontakt:
        • Ledende efterforsker:
          • Katherine Antel
      • Easley, South Carolina, Forenede Stater, 29640
        • Rekruttering
        • Prisma Health Cancer Institute - Easley
        • Ledende efterforsker:
          • Suzanne R. Fanning
        • Kontakt:
      • Greenville, South Carolina, Forenede Stater, 29605
        • Rekruttering
        • Prisma Health Cancer Institute - Faris
        • Ledende efterforsker:
          • Suzanne R. Fanning
        • Kontakt:
      • Greenville, South Carolina, Forenede Stater, 29605
        • Rekruttering
        • Prisma Health Cancer Institute - Butternut
        • Ledende efterforsker:
          • Suzanne R. Fanning
        • Kontakt:
      • Greenville, South Carolina, Forenede Stater, 29615
        • Rekruttering
        • Prisma Health Cancer Institute - Eastside
        • Ledende efterforsker:
          • Suzanne R. Fanning
        • Kontakt:
      • Greer, South Carolina, Forenede Stater, 29650
        • Rekruttering
        • Prisma Health Cancer Institute - Greer
        • Ledende efterforsker:
          • Suzanne R. Fanning
        • Kontakt:
      • Seneca, South Carolina, Forenede Stater, 29672
        • Rekruttering
        • Prisma Health Cancer Institute - Seneca
        • Ledende efterforsker:
          • Suzanne R. Fanning
        • Kontakt:
    • South Dakota
      • Sioux Falls, South Dakota, Forenede Stater, 57104
      • Sioux Falls, South Dakota, Forenede Stater, 57117-5134
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • Huntsman Cancer Institute/University of Utah
        • Kontakt:
        • Ledende efterforsker:
          • Harsh Shah
    • Vermont
      • Saint Johnsbury, Vermont, Forenede Stater, 05819
        • Rekruttering
        • Dartmouth Cancer Center - North
        • Kontakt:
        • Ledende efterforsker:
          • Charles Gaulin
    • Virginia
      • Richmond, Virginia, Forenede Stater, 23235
        • Rekruttering
        • VCU Massey Cancer Center at Stony Point
        • Kontakt:
        • Ledende efterforsker:
          • Bruce O. Hough
      • Richmond, Virginia, Forenede Stater, 23298
        • Rekruttering
        • VCU Massey Comprehensive Cancer Center
        • Ledende efterforsker:
          • Bruce O. Hough
        • Kontakt:
    • Washington
      • Edmonds, Washington, Forenede Stater, 98026
        • Rekruttering
        • Swedish Cancer Institute-Edmonds
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Issaquah, Washington, Forenede Stater, 98029
        • Rekruttering
        • Swedish Cancer Institute-Issaquah
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
      • Seattle, Washington, Forenede Stater, 98122
        • Rekruttering
        • Swedish Medical Center-First Hill
        • Ledende efterforsker:
          • Alison K. Conlin
        • Kontakt:
    • Wisconsin
      • Appleton, Wisconsin, Forenede Stater, 54911
        • Rekruttering
        • ThedaCare Regional Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Yazhini Vallatharasu
      • Appleton, Wisconsin, Forenede Stater, 54911
        • Rekruttering
        • ThedaCare Regional Medical Center - Appleton
        • Kontakt:
        • Ledende efterforsker:
          • Yazhini Vallatharasu
      • Ashland, Wisconsin, Forenede Stater, 54806
        • Rekruttering
        • Duluth Clinic Ashland
        • Kontakt:
        • Ledende efterforsker:
          • Bret E. Friday
      • Eau Claire, Wisconsin, Forenede Stater, 54701
      • Johnson Creek, Wisconsin, Forenede Stater, 53038
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center - Johnson Creek
        • Ledende efterforsker:
          • Priyanka Pophali
        • Kontakt:
      • La Crosse, Wisconsin, Forenede Stater, 54601
        • Rekruttering
        • Gundersen Lutheran Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Michael O. Ojelabi
      • Madison, Wisconsin, Forenede Stater, 53792
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Ledende efterforsker:
          • Priyanka Pophali
        • Kontakt:
      • Madison, Wisconsin, Forenede Stater, 53718
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
        • Ledende efterforsker:
          • Priyanka Pophali
        • Kontakt:
      • Marshfield, Wisconsin, Forenede Stater, 54449
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Rekruttering
        • Medical College of Wisconsin
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 414-805-3666
        • Ledende efterforsker:
          • Mehdi Hamadani
      • Minocqua, Wisconsin, Forenede Stater, 54548
      • Mukwonago, Wisconsin, Forenede Stater, 53149
        • Rekruttering
        • ProHealth D N Greenwald Center
        • Kontakt:
        • Ledende efterforsker:
          • Timothy R. Wassenaar
      • New Berlin, Wisconsin, Forenede Stater, 53151
        • Rekruttering
        • Froedtert and MCW Moorland Reserve Health Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 414-805-0505
        • Ledende efterforsker:
          • Mehdi Hamadani
      • Oconomowoc, Wisconsin, Forenede Stater, 53066
        • Rekruttering
        • ProHealth Oconomowoc Memorial Hospital
        • Ledende efterforsker:
          • Timothy R. Wassenaar
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 262-928-7878
      • Rice Lake, Wisconsin, Forenede Stater, 54868
      • Stevens Point, Wisconsin, Forenede Stater, 54482
      • Waukesha, Wisconsin, Forenede Stater, 53188
        • Rekruttering
        • UW Cancer Center at ProHealth Care
        • Ledende efterforsker:
          • Timothy R. Wassenaar
        • Kontakt:
      • Weston, Wisconsin, Forenede Stater, 54476

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

60 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • • Histologically confirmed mantle cell lymphoma with cyclin D1 (BCL1) expression by immunohistochemical stains and/or evidence of CCND1 rearrangement or t(11;14)(q13;q32) as confirmed by the enrolling center (such as by fluorescence in situ hybridization [FISH], polymerase chain reaction [PCR]/sequencing, karyotype). Patients with cyclin D1 and/or t(11;14) negative mantle cell lymphoma with an expression profile suggesting a diagnosis of mantle cell lymphoma [MCL] such as SOX11 expression are also eligible

    • Any stage allowed (stage I-IV)

      • Patient must have at least one objective measurable disease parameter by PET or CT. Measurable disease in the liver is required if the liver is the only site of lymphoma OR bone marrow involvement by MCL
      • Steroids for management of mantle cell lymphoma are allowed up to a dose of prednisone 100mg/day (or equivalent) for up to 7 days prior to registration
      • No prior systemic treatment for mantle cell lymphoma
      • No prior radiation treatment for stage I MCL
      • No prior exposure to a BTK inhibitor or anti-CD20 monoclonal antibody
      • No prior stem cell transplant
      • Age >= 70 years OR age >= 60 to < 70 years with comorbidities precluding autologous stem cell transplantation (autoSCT) including at least one of the following: a) cardiac ejection fraction (EF) <= 45%, b) diffusing capacity for carbon monoxide <= 60% predicted; c) creatinine clearance < 70 but >= 30ml/minute (min); d) Eastern Cooperative Oncology Group (ECOG) performance status of 2, which poses an unacceptable risk of toxicity for high-dose therapy and stem cell transplantation; or e) Cumulative Illness Rating Scales (CIRS) total score > 6
      • ECOG Performance Status 0-2
      • Absolute neutrophil count (ANC) >= 750/mm^3 (without growth factor support within 7 days)
      • Platelet count >= 75,000/mm^3 (or >= 50,000/mm^3 if thrombocytopenia is due to lymphoma) without growth factor support or transfusion within 7 days
      • Creatinine clearance >= 30 mL/ min determined by either: a) Estimation using the Cockcroft-Gault equation or b) Measurement by nuclear medicine scan or 24 hour urine collection
      • Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless documented Gilbert's syndrome)
      • Aspartate transferase (AST) / alanine transaminase (ALT) =< 3 x ULN
      • Patients should not be considered candidates for stem cell transplant or must have declined a stem cell transplant strategy
      • No clinically significant cardiovascular disease including the following
    • Unstable angina within 3 months before registration

    • New York Heart Association class III or IV congestive heart failure

    • History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)

    • Known QT correction formula (QTcF) > 480 msecs based on Fredericia's formula (unless pacemaker in place)

    • History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place

      • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
      • No active Hepatitis B or Hepatitis C infection. Patients with prior hepatitis B virus (HBV) exposure (positive HBV core antibody and/or surface antigen) are eligible if they have no detectable viral load, and are taking appropriate prophylactic antiviral therapy to prevent reactivation. Patients with history of hepatitis C virus (HCV) are eligible if they have an undetectable HCV viral load
      • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
      • No history of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention
      • No history of stroke or intracranial hemorrhage within 6 months prior to registration
      • No disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. Patient must be able to swallow pills
      • Potential trial participants should have recovered from major surgery
      • No vaccination with a live vaccine within 35 days prior to registration
      • No hypersensitivity to zanubrutinib or rituximab or any of the other ingredients of the study drugs
      • Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study.
      • Patients on strong CYP3A4 inducers must discontinue the drug 14 days prior to registration.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Induction therapy (Zanubrutinib, rituximab)

Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.

Undergo blood sample collection

Given IV

Undergo CT

Andre navne:
  • CAT-scanning
  • CT-scanning

Undergo MRI

Andre navne:
  • MR

Ancillary studies

Undergo PET

Andre navne:
  • KÆLEDYR

Undergo colonoscopy

Undergo observation

Undergo EGD

Andre navne:
  • EGD

Given PO

undergo bone marrow biopsy

Given IV

Eksperimentel: Arm A (Zanubrutinib)

Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.

Undergo blood sample collection

Undergo CT

Andre navne:
  • CAT-scanning
  • CT-scanning

Undergo MRI

Andre navne:
  • MR

Ancillary studies

Undergo PET

Andre navne:
  • KÆLEDYR

Undergo colonoscopy

Undergo observation

Undergo EGD

Andre navne:
  • EGD

Given PO

undergo bone marrow biopsy

Given IV

Aktiv komparator: ARM B (Observation)

Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.

Undergo blood sample collection

Undergo CT

Andre navne:
  • CAT-scanning
  • CT-scanning

Undergo MRI

Andre navne:
  • MR

Ancillary studies

Undergo PET

Andre navne:
  • KÆLEDYR

Undergo colonoscopy

Undergo observation

Undergo EGD

Andre navne:
  • EGD

Given PO

undergo bone marrow biopsy

Given IV

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-free survival (PFS) 1 (Arm A)
Tidsramme: Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years

Hazard ratios on the treatment effect will be estimated using a stratified cox proportional hazards model, stratified on age and mantle cell lymphoma (MCL) International Prognostic Index (IPI) score. The primary analysis for non-inferiority will be based on an intent-to-treat (ITT) analysis and will include all randomized patients in the analyses, regardless of eligibility or treatment status. Sensitivity analyses will also be done in an ancillary manner to evaluate and compare our endpoints using a modified ITT approach, and exclude from the analysis those classified as ineligible as well as those who withdraw right after randomization prior to any treatment/observation monitoring.

Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years
Progression-free survival (PFS) 2 (Arm B)
Tidsramme: Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years

Hazard ratios on the treatment effect will be estimated using a stratified cox proportional hazards model, stratified on age and MCL IPI score. The primary analysis for non-inferiority will be based on an ITT analysis and will include all randomized patients in the analyses, regardless of eligibility or treatment status. Sensitivity analyses will also be done in an ancillary manner to evaluate and compare our endpoints using a modified ITT approach, and exclude from the analysis those classified as ineligible as well as those who withdraw right after randomization prior to any treatment/observation monitoring.

Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall survival (OS) (Arms A and B)
Tidsramme: Time from randomization until death from any cause, assessed up to 10 years

Kaplan-Meier methodology will be used to estimate the distributions of OS by treatment arm and log-rank test statistics will be used to compare these distributions between the two treatment arms. Cox Proportional Hazards models may be used to further evaluate covariates of interest with OS, including assessment of treatment effects when adjusting for other known risk factors in the model.

Time from randomization until death from any cause, assessed up to 10 years
Incidence of adverse events
Tidsramme: Up to 10 years

Will be evaluated and captured using the CTCAE 5.0, where the type and severity grade of each adverse event will be collected and tabulated within each of the treatment arms. Perceived attribution to study treatment will also be captured.

The analysis population for this secondary endpoint will include all patients who are registered and randomized on the study and receive at least one dose of study treatment. Adverse events will be monitored continuously throughout the course of the study as well as analyzed at the time of the final primary endpoint analysis.

Summary statistics and frequency tables will be used to describe the distributions of adverse events. Rates of adverse events occurring in compared across the treatment arms with chi-squared tests Tolerability will also be evaluated, summarizing rates of dose delays or modifications, reasons patients end treatment, and time to end of active treatment.

Up to 10 years
Overall response rate (ORR, complete + partial remission)
Tidsramme: up to 10 years

Will be assessed using Lugano criteria. ORR to induction is defined as the number of patients with complete or partial remission at the end of induction divided by the number of patients who receive at least one dose of the induction regimen. ORR to restart of zanubrutinib is only defined for Arm B, as the number of patients with complete or partial remission after restart of zanubrutinib divided by the number of patients that restart zanubrutinib after first disease progression following randomization. The frequencies and rates of tumor response categories will be summarized by treatment arm for response to induction as well as response to restart of zanubrutinib (Arm B only). ORR to induction and ORR to restart of zanubrutinib (Arm B only) with 95% exact binomial confidence intervals will be calculated by treatment arm. To compare the association of treatment arm and ORR to induction, chi-squared or Fisher's Exact test will be used, whichever is more appropriate at final analysis.

up to 10 years
Complete response rate (CR)
Tidsramme: Up to 10 years

Will be assessed using Lugano criteria. CR to induction is defined as the number of patients with complete remission at the end of induction divided by the number of eligible patients who receive at least one dose of the induction regimen. CR to restart of zanubrutinib is only defined for Arm B, as the number of patients with complete remission after restart of zanubrutinib divided by the number of eligible patients that restart zanubrutinib after first disease progression following randomization. CR to induction and CR to restart of zanubrutinib (Arm B patients only) with 95% exact binomial confidence intervals will be calculated by treatment arm. To compare the association of treatment arm and CR to induction, chi-squared or Fisher's Exact test will be used, whichever is more appropriate at the time of the final analysis.

Up to 10 years
Event-free survival (EFS) 1
Tidsramme: Time from randomization (Arms A and B) until the earlier of first progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.

For EFS1, patients without an event will be censored at the last known clinical assessment. Any patient who goes to transplant will be censored at the last known clinical assessment prior to transplant. Kaplan-Meier methodology will be used to estimate the distribution of EFS. Cox Proportional Hazards models may be used to further evaluate covariates of interest with EFS.

Time from randomization (Arms A and B) until the earlier of first progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
Event-free survival (EFS) 2
Tidsramme: Time from randomization (Arm B) until the earlier of second progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.

For EFS2, patients without an event will be censored at the last known clinical assessment. Any patient who goes to transplant will be censored at the last known clinical assessment prior to transplant. Kaplan-Meier methodology will be used to estimate the distribution of EFS. Cox Proportional Hazards models may be used to further evaluate covariates of interest with EFS.

Time from randomization (Arm B) until the earlier of second progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. oktober 2023

Primær færdiggørelse (Anslået)

31. august 2038

Studieafslutning (Anslået)

31. august 2038

Datoer for studieregistrering

Først indsendt

26. juli 2023

Først indsendt, der opfyldte QC-kriterier

26. juli 2023

Først opslået (Faktiske)

4. august 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • A052101
  • NCI-2023-03577 (Anden identifikator: NCI Clinical Trial Reporting Program)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .